A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia

Hematological Oncology

Volumn 19, Issue 3, 2001, Pages 89-106

  Macheta, M ^a   Yin, J A Liu ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD34 ANTIGEN; COLONY STIMULATING FACTOR; DNA; DOUBLE STRANDED DNA; F ACTIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HLA DR ANTIGEN; HOE 33342; HYBRID PROTEIN; IMATINIB; INTEGRIN; INTERFERON RECEPTOR; INTERLEUKIN 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PYRONINE; RAS PROTEIN; RNA; RNA DIRECTED DNA POLYMERASE; STAT PROTEIN; TELOMERASE; TYROSINE;

APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL ADHESION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TELOMERE;

ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PHILADELPHIA CHROMOSOME; SIGNAL TRANSDUCTION; STEM CELLS; TELOMERE; TUMOR STEM CELLS;

EID: 0034781268     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.667     Document Type: Review

References (105)

1. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood
2. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
3. A minute chromosome in human chronic granulocytic leukemia
4. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
5. Fused transcript of abl and bcr genes in chronic myelogenous leukemia
6. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
7. + chronic myelogenous leukemia and effects of intensive treatment
8. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia
9. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia
10. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
11. Chronic myeloid leukemia
12. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
13. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
14. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
15. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
16. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells
17. Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content
18. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment
19. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry
20. Short telomeres on human chromosome 17p
21. Structure and function of telomeres
22. Functional failures of cultured human diploid fibroblasts after continued population doublings
23. Human cells and aging
24. Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells
25. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age
26. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
27. Essential role of mouse telomerase in highly proliferative organs
28. Telomerase activity in normal and malignant hematopoietic cells
29. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow
30. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow
31. Regulation of telomere length and telomerase in T and B cells: A mechanism for maintaining replicative potential
32. Telomerase activity in human cancer
33. Extension of life-span by introduction of telomerase into normal human cells
34. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
35. Correlating telomerase activity levels with human neuroblastoma outcomes
36. Ontogeny-related changes in proliferative potential of human hematopoietic cells
37. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood
38. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants
39. Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation
40. Telomere length changes in patients undergoing hematopoietic stem cell transplants
41. In vivo telomere dynamics of human hematopoietic stem cells
42. Changes of telomere length in children after hematopoietic stem cell transplant
43. Chromosome studies on normal and leukemic human leukocytes
44. Acute leukemia in bcr/abl transgenic mice
45. bcr-abl, hallmark of chronic myeloid leukemia in man, induces multiple hemopoietic neoplasms in mice
46. bcr/abl gene of the Philadelphia chromosome
47. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
48. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
49. The molecular biology of chronic myeloid leukemia
50. Chronic myeloid leukemia from basics to bedside
51. ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukemia
52. Interferon response in chronic myeloid leukemia correlates with ABL/BCR expression: A preliminary study
53. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukemia
54. Abl tyrosine kinase
55. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation
56. BCR/ABL to the phosphatidylinositol-3′ kinase pathway
57. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells
58. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells
59. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
60. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
61. c subunit and constitutively induces its tyrosine phosphorylation
62. Constitutive activation of JAKS and STATS in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
63. Differences between normal and CML stem cells: Potential targets for clinical exploitation
64. BCR-ABL oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia
65. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism
66. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
67. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression
68. Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder
69. Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells
70. Steel factor and Flk-2/Flt-3 ligand alone trigger quiescent human LTC-IC into S-phase more effectively than primitive quiescent clonogenic progenitor cells
71. Discordant maturation as the primary biological defect in chronic myelogenous leukemia
72. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
73. BCR-ABL accelerates C2-ceramide-induced apoptosis
74. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
75. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and Pyronin Y
76. - cell production in vitro
77. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myleoid leukemia
78. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
79. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia
80. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression
81. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture
82. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
83. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
84. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr-abl protein
85. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
86. The suppression of drug-induced apoptosis by activation of v-abl protein tyrosine kinase
87. Apoptosis in chronic myeloid leukemia: Normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids
88. BCR-ABL does not prevent apoptotic cell death induced by natural killer or lymphokine-activated killer cells
89. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia
90. Activation of β1 integrins on CML progenitors reveals cooperation between β1 integrins and CD44 in the regulation of adhesion and proliferation
91. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL
92. BCR/ABL induces multiple abnormalities of cytoskeletal function
93. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells
94. 1 integrin receptor function
95. Protein kinase inhibitors: Probes for the functions of protein phosphorylation
96. Tyrosine protein kinase inhibition and cancer
97. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
98. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
99. In vivo eradication of human BCR/ABL positive leukemia cells with an ABL kinase inhibitor
100. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
101. Activity of an Abl specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
102. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
103. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL transformed hematopoietic cell lines
104. Efficacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents, against BCR-ABL positive cells